PVC Allergy: Why the Polymer Is Innocent and the Additives Are the Problem
Polyvinyl chloride (PVC) polymer is chemically inert and not a contact sensitizer. Reactions attributed to PVC products are caused by additives — particularly phthalate plasticizers (DEHP, DBP), heat stabilizers, and antimicrobials added to the polymer during manufacture. A PVC factory study found 11 of 401 workers with allergic contact dermatitis, with 6 specifically sensitized to phthalates. If you react to flexible PVC products, phthalates are the most likely culprit.
Free · 5 min · Insurance accepted
Key facts
PVC polymer is chemically inert and not a contact sensitizer; a PVC factory study found 11 of 401 workers with allergic contact dermatitis, with 6 specifically sensitized to phthalate plasticizer additives.
Phthalates DEHP, DBP, BBP, and DIBP are classified by the EU as Substances of Very High Concern under REACH, restricted to ≤0.1% in consumer articles due to endocrine-disrupting properties.
DEHP use in medical devices faces EU prohibition by July 2030 — a major regulatory shift affecting IV bags, medical tubing, and blood storage products that currently contain PVC with phthalate plasticizers.
The carbon disulfide (CS₂) used in rayon/viscose and formerly in PVC processing is a potent occupational neurotoxin, but no residual CS₂ survives in finished consumer products after manufacturing.
What Is PVC Allergy? (Hint: It's Not the PVC)
Polyvinyl chloride (PVC) allergy is a misnomer.
PVC polymer — the base plastic material — is chemically inert at the molecular level and is not a contact sensitizer. No documented cases of true allergic contact dermatitis caused by the PVC polymer itself exist in the clinical literature. When patients experience skin reactions from PVC products, the responsible agents are invariably additives incorporated into the polymer during manufacture.
PVC in its pure form is a rigid, brittle material unsuitable for most consumer and medical applications. To make it flexible and useful, manufacturers add a range of chemical additives: plasticizers (primarily phthalates) to increase flexibility, heat stabilizers (historically lead or tin compounds, increasingly calcium-zinc systems) to prevent degradation during processing, antimicrobials to prevent microbial growth in soft formulations, and pigments for coloration.
The phthalates — particularly DEHP (di(2-ethylhexyl) phthalate), DBP (dibutyl phthalate), BBP (benzyl butyl phthalate), and DEP (diethyl phthalate) — are the primary culprits when flexible PVC products cause skin reactions. In the most cited clinical study examining this question, a PVC factory study found allergic contact dermatitis in 11 of 401 workers, with 6 specifically sensitized to phthalates — confirming the additive-not-polymer hypothesis in an occupational setting.
The PVC-and-phthalates story is also significant beyond contact allergy: phthalates are recognized endocrine disruptors with anti-androgenic and reproductive toxicity effects. The EU has classified DEHP, DBP, BBP, and DIBP as Substances of Very High Concern (SVHCs) under REACH, restricting them to ≤0.1% in consumer articles. DEHP use in medical devices faces EU prohibition by July 2030 — a major regulatory shift affecting IV bags, medical tubing, and blood storage products.
PVC-Associated Contact Dermatitis Symptoms
Recognizing symptoms early helps you get the right treatment faster.
Foot dermatitis
mildRedness, pruritus, and vesicles on the soles and dorsal feet from phthalate-plasticized PVC shoe insoles or footwear lining — a classic presentation of shoe contact dermatitis.
Wrist dermatitis
mildContact dermatitis on the skin under PVC watchstraps, fitness tracker bands, or wristbands containing phthalate plasticizers.
Medical device site reaction
moderateContact dermatitis at the site of PVC medical tubing, IV line contact, or PVC-containing dressing adhesive backing — may require urgent material substitution in clinical settings.
Occupational hand and forearm dermatitis
moderateEczematous rash on the hands and forearms in PVC manufacturing workers from occupational contact with plasticizers during compounding and processing.
Contact dermatitis from PVC flooring
mildWorkers who kneel, sit, or have prolonged skin contact with plasticized PVC flooring may develop knee, leg, or hand dermatitis from plasticizer transfer.
Pruritus
mildItching at the PVC contact site, typically appearing 24–96 hours after exposure as part of the Type IV delayed reaction.
When to see a doctor
Because the polymer itself is inert, PVC-associated contact dermatitis presents at the specific sites of prolonged flexible PVC contact — where plasticizer and additive leaching into skin occurs over time. Common contact sites include: feet (from PVC shoe insoles or footwear lining), wrists (from PVC watchstraps or wristbands), torso and thighs (from PVC flooring in occupational settings), and medical device contact sites in clinical populations. The symptoms follow the typical Type IV contact dermatitis pattern: erythema, papules, vesicles, and pruritus appearing 24–96 hours after exposure at the contact site. In occupational workers with daily exposure, the reaction pattern follows work days. Medical device-associated reactions present at catheter insertion sites, beneath adhesive dressings with PVC-backed foam, or along the skin contact path of IV tubing in restricted patients. These presentations should be reported to healthcare providers immediately, as they may require urgent material substitution. PVC contact allergy is mild to moderate in most cases. Severe systemic reactions are not a recognized feature. However, any unexplained rash at a medical device contact site should receive prompt medical evaluation.
PVC, Phthalates, and Respiratory Health
PVC itself is not an aeroallergen. However, the thermal degradation products of PVC — including hydrogen chloride and other volatile compounds released when PVC burns or is thermally processed — are respiratory irritants that can cause acute upper and lower respiratory tract irritation. Phthalates as volatile compounds (particularly DEHP) are measurable in indoor air, especially in enclosed spaces with large PVC surface areas (new car interiors, freshly installed PVC flooring). Epidemiological studies have suggested associations between indoor phthalate levels and increased asthma risk in children, though causality is debated. The proposed mechanism involves phthalate enhancement of IgE-mediated allergic sensitization (an adjuvant effect) rather than direct airway sensitization. For patients with established asthma considering PVC product choices, reducing phthalate exposure in home environments — by choosing non-PVC or low-phthalate alternatives for flooring, toys, and soft furnishings — is a reasonable precautionary approach, though the evidence for direct asthma benefit is not definitive.
Complications of PVC Additive Sensitivity
The key complication of PVC additive contact allergy is diagnostic confusion: because consumers expect PVC to be the allergen, they may attempt to avoid all PVC products — including rigid PVC pipes, cable insulation, and structural applications that contain no plasticizers and pose no sensitization risk. The correctly targeted approach is to avoid flexible, highly plasticized PVC products and work toward identifying the specific additive responsible through patch testing. The phthalate story has additional complexity because phthalates are regulated differently across jurisdictions and product categories. A product compliant with US regulations may contain phthalate levels prohibited under EU REACH for consumer articles. Patients who travel internationally or purchase products from different regulatory environments may face variable exposures. Systemic phthalate exposure from prolonged medical device use — a concern particularly for neonates and critically ill patients with high IV fluid requirements — is a regulatory priority being addressed through the EU DEHP medical device prohibition scheduled for July 2030.
Diagnostic confusion and over-avoidance
Patients who avoid all PVC without identifying the specific additive allergen may restrict unnecessarily from rigid PVC products (inert, no plasticizers) while failing to identify other phthalate-containing products outside PVC.
Medical device management challenges
Phthalate sensitization can require urgent substitution of PVC medical tubing, IV bags, or catheter materials in hospital settings — requiring rapid identification and procurement of DEHP-free alternatives.
Ongoing endocrine exposure concern
Phthalate endocrine disruption effects persist independently of contact sensitization; patients concerned about reproductive or developmental effects should discuss broader phthalate exposure reduction with their physician.
Regulatory transition risks
As DEHP is replaced under EU/US regulation, substitute plasticizers (DINP, DIDP, DPHP) are introduced; their long-term sensitization and endocrine profiles are less well characterized, creating uncertainty for sensitized patients.
What Actually Causes PVC-Associated Skin Reactions?
When a patient experiences dermatitis from a PVC product, the investigation must focus on the additives rather than the base polymer. The composition of flexible PVC varies substantially by product category:
How it works
PVC polymer itself cannot act as a hapten — its repeating chloroethylene units have no chemically reactive groups capable of binding to skin proteins under physiological conditions. When contact allergy is attributed to PVC products, phthalate plasticizers serve as the actual haptens. Phthalates may themselves have low haptenation potential, or reactive metabolites produced during skin biotransformation may be the sensitizing species. The resulting T-cell-mediated sensitization follows the standard Type IV pathway: hapten-protein conjugate formation, Langerhans cell processing, T-lymphocyte sensitization in regional lymph nodes, and delayed eczematous reaction 24–96 hours after re-exposure.
In consumer products (shower curtains, inflatable items, raincoats, flooring, furniture upholstery), the plasticizer content can be 20–40% by weight. DEHP was historically the dominant plasticizer; regulatory pressure has driven substitution to DINP, DIDP, and other alternatives, though their sensitization profiles are less thoroughly characterized.
In medical devices (IV bags, medical tubing, blood storage products, catheters), DEHP has been the primary plasticizer for decades due to its excellent performance characteristics. The leaching of DEHP from PVC medical devices into IV fluids and blood products has been a concern for high-risk populations — neonates, patients with high IV fluid intake. EU prohibition by July 2030 will drive substitution in this critical application.
In children's toys, both the EU and US CPSIA permanently ban DEHP, DBP, and BBP at concentrations above 0.1%, reflecting concern about phthalate exposure in children who mouth toys.
Rigid PVC products (pipes, window profiles, cable insulation) contain little or no plasticizer and present much lower sensitization risk than flexible PVC formulations.
Risk factors to watch for
Occupational PVC manufacturing
Workers in PVC compounding, processing, and product manufacturing face the highest concentration additive exposures; the 11/401 ACD rate in the PVC factory study reflects this occupational risk.
Prolonged skin contact with flexible PVC
Products with extended, direct skin contact — medical tubing, wristwatch straps, shoe insoles, gloves, prolonged contact with PVC flooring — present higher sensitization risk than brief contacts.
High-plasticizer flexible PVC products
Soft, pliable PVC products (shower curtains, inflatable items, soft toys, medical tubing) contain the highest plasticizer concentrations and leach more additive under heat and moisture conditions.
Prolonged medical device exposure
Patients with extensive IV line use, parenteral nutrition, or blood product administration through PVC tubing receive the highest medical-device DEHP exposures; neonatal ICU patients are particularly high-risk.
Atopic history
Individuals with compromised skin barrier from atopic dermatitis may absorb phthalates more readily through disrupted skin, increasing sensitization risk with prolonged PVC contact.
The Allergy Cascade
Exposure
Allergen contact
Detection
Immune recognition
IgE Response
Antibody production
Mast Cells
Histamine release
Symptoms
Allergic reaction
1.Exposure
Allergen contact
2.Detection
Immune recognition
3.IgE Response
Antibody production
4.Mast Cells
Histamine release
5.Symptoms
Allergic reaction
Diagnosing PVC and Phthalate Contact Allergy
Diagnosing PVC-associated contact allergy requires targeted patch testing for the relevant additives, not for PVC polymer itself. The approach begins with identifying the specific PVC product involved and reviewing its additive composition — plasticizer type, heat stabilizers, and antimicrobials are the primary investigation targets. Phthalates (DEHP, DBP, BBP) may be tested in an extended allergen panel by a dermatologist familiar with plastic additive allergy. Standard NACDG and European baseline series do not include phthalates, so specific clinical suspicion and extended testing are required. The dermatologist may request safety data sheets or product composition information from the manufacturer. For medical device-associated reactions in healthcare settings, the hospital's material management team and the device manufacturer should be contacted immediately to identify DEHP-free alternatives. Clinical toxicology may be involved for high-risk patients with systemic phthalate concerns. At-home IgE allergy testing such as Curex's 40+ allergen panel covers IgE-mediated respiratory and food allergens, not the Type IV contact mechanism of phthalate sensitization. Contact allergy to PVC additives requires in-person dermatologist patch testing.
Extended Patch Testing (Phthalates)
DEHP, DBP, BBP, and relevant PVC additives tested at appropriate concentrations in an extended panel when PVC-associated contact dermatitis is suspected. Not in standard NACDG or European baseline series.
Product Composition Review
Review of the specific PVC product's safety data sheet or manufacturer ingredient disclosure to identify which plasticizers, stabilizers, and antimicrobials are present.
Repeat Open Application Test (ROAT)
After patch test positivity for a specific additive, a ROAT with the suspect product applied to an elbow crease twice daily for 1–2 weeks confirms clinical relevance.
Test from home with Curex
Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.
Take the allergy quizCompare Treatment Options
See how different approaches stack up for managing your allergy symptoms long-term.
Traditional
Allergy Shots (SCIT)
Immunotherapy (SLIT)
RecommendedTreats root cause
Long-lasting relief
At-home treatment
No office visits
Low side effects
Estimated cost
Traditional
- Treats root cause
- Long-lasting relief
- At-home treatment
- No office visits
- Low side effects
- Estimated cost
Allergy Shots (SCIT)
- Treats root cause
- Long-lasting relief
- At-home treatment
- No office visits
- Low side effects
- Estimated cost
Immunotherapy (SLIT)
Recommended- Treats root cause
- Long-lasting relief
- At-home treatment
- No office visits
- Low side effects
- Estimated cost
The long-term solution to allergies
Instead of masking symptoms, immunotherapy retrains your immune system.
Phthalate and PVC additive contact allergy operates through T-cell delayed hypersensitivity — the same machinery as other contact allergens — which means there is no SCIT or SLIT protocol that addresses this sensitization. PVC additive contact allergy (phthalate contact dermatitis) is a Type IV T-cell-mediated delayed hypersensitivity reaction, not IgE-mediated. Allergen immunotherapy is not a standard treatment for Type IV contact allergies, and no SLIT or SCIT protocols exist for phthalate sensitization. For patients who have phthalate contact allergy alongside IgE-mediated respiratory allergies, the IgE-mediated conditions can be addressed independently with sublingual immunotherapy. Providers like Curex offer at-home SLIT drops starting at $39/month for confirmed IgE-mediated allergens, formulated by board-certified allergists for convenient at-home use. These address the respiratory allergy component while phthalate avoidance manages the contact allergy. Management of PVC additive contact allergy is through accurate allergen identification and sustained product avoidance.
Identify the Specific PVC Product
Determine which PVC product is causing your reaction — the specific additive composition (which phthalate, which stabilizer) varies by product and is the critical diagnostic information.
Extended Patch Testing
Request extended patch testing including phthalates and relevant PVC additives from a board-certified dermatologist who specializes in contact allergy.
Switch to Non-PVC or Phthalate-Free Alternatives
Replace confirmed phthalate-containing products with silicone, polyurethane, or verified phthalate-free alternatives. Rigid PVC products (pipes, frames) are generally safe to keep.
Treat Active Dermatitis
Use physician-prescribed topical corticosteroids and barrier emollients for active skin inflammation while transitioning to phthalate-free products.
“Targeted avoidance of specific sensitizing additives leads to resolution in most contact dermatitis patients”
Treat your PVC allergy at the source
See if at-home sublingual allergy drops fit your allergies — a 2-minute quiz, designed by board-certified allergists, with no needles and no clinic visits.
- 4.8/5Patient rating
- From $39/moWith insurance
- 50K+Patients treated
- HSA/FSAEligible
Living With PVC Additive Sensitivity
Understanding that PVC polymer itself is inert — and that the additives are the actual issue — is the most important reframe for patients diagnosed with PVC-associated contact allergy. This insight focuses avoidance precisely and prevents unnecessary restriction from harmless rigid PVC items. The growing market for phthalate-free consumer products — driven by EU regulation, parental concern, and sustainability trends — makes phthalate avoidance increasingly practical across most product categories. Silicone watchstraps, thermoplastic rubber shoe soles, and DEHP-free medical devices are widely available and often superior performers to phthalate-plasticized PVC alternatives. For those managing phthalate sensitivity alongside the broader endocrine disruption concern, a precautionary approach of minimizing high-phthalate flexible PVC items in regular skin contact provides both allergy protection and endocrine exposure reduction without being excessively restrictive.
The PVC Paradox: Polymer vs. Additives
Pure PVC polymer is inert. The problem is the cocktail of plasticizers, stabilizers, and antimicrobials added to make it flexible and durable. Focus your avoidance on flexible, highly plasticized PVC products — not on avoiding all PVC everywhere.
Silicone Is a Reliable Alternative
Silicone rubber is an excellent alternative to flexible PVC for watchstraps, wristbands, medical tubing, and many other skin-contact applications. It is chemically inert, durable, and generally well-tolerated by phthalate-sensitive individuals.
Communicate with Your Medical Team
If you require IV therapy or other PVC medical device use, mention your PVC additive sensitivity to your healthcare team. DEHP-free alternatives exist for most medical applications and are increasingly available as the EU 2030 prohibition approaches.
Watch for Related Endocrine Information
Phthalate endocrine disruption is an active regulatory and research area. Stay informed through your physician, and note that the allergy concern (skin sensitization) and the endocrine concern (hormonal effects) are separate issues requiring different management considerations.
Seasonal Patterns
January - December
low intensity
Prevention Tips
Choose DEHP-Free Products for Prolonged Skin Contact
For products in long-duration skin contact — watchstraps, shoes, wrist fitness monitors, children's toys — specifically look for DEHP-free, phthalate-free, or non-PVC materials (silicone, thermoplastic rubber).
Rigid PVC Is Generally Safe
Rigid PVC (pipes, cable insulation, window profiles, credit cards) contains minimal or no plasticizers and presents essentially no sensitization risk. Avoidance of rigid PVC is unnecessary.
Request DEHP-Free Medical Devices
Patients requiring significant IV therapy, particularly neonates and those requiring parenteral nutrition, should discuss DEHP-free medical device availability with their healthcare team.
Ventilate Freshly Installed PVC Flooring
New flexible PVC flooring and vinyl products off-gas plasticizers at higher rates initially. Ventilating rooms well for several weeks after installation reduces inhalation and surface exposure.
Occupational Protective Equipment
PVC manufacturing workers should use appropriate skin protection including nitrile gloves and barrier creams to minimize additive skin contact during compounding and processing.
Prognosis for PVC Additive Contact Allergy
The prognosis for confirmed PVC additive contact allergy is generally excellent, given the focused nature of the required avoidance. Once the specific additive (typically a phthalate) is confirmed by patch testing, targeted product avoidance leads to resolution of contact dermatitis without requiring broad PVC avoidance. The regulatory trajectory — DEHP restriction under EU REACH, prohibition in medical devices, ongoing elimination from children's products — is reducing phthalate exposure opportunities across consumer product categories. This makes future accidental exposures less likely and future product selection more straightforward. Sensitization is typically persistent, but with the growing availability of phthalate-free alternatives, managing PVC additive contact allergy is becoming progressively less burdensome.
Key takeaways
PVC polymer is chemically inert and not a contact sensitizer — reactions are from additives, primarily phthalate plasticizers
A PVC factory study confirmed 11/401 ACD cases with 6 specifically sensitized to phthalates
Rigid PVC (pipes, cables, structural profiles) contains no plasticizers and presents no sensitization risk
DEHP is classified as SVHC under EU REACH (≤0.1% in consumer articles) and faces EU prohibition in medical devices by July 2030
Targeted avoidance of phthalate-containing flexible PVC products resolves dermatitis while allowing continued use of rigid PVC items
When patients report rash from flexible PVC gloves, IV tubing, or clothing, the polymer itself is not the sensitizer — the phthalate plasticizers DEHP and DBP are the most likely culprits. Patch testing with phthalate compounds and switching to phthalate-free PVC or alternative materials resolves the problem in most cases.
Frequently Asked Questions
PVC allergy is actually an allergy to additives in PVC products — primarily phthalate plasticizers — not to the PVC polymer itself. PVC polymer is chemically inert and not a contact sensitizer. When people develop contact dermatitis from PVC products, the responsible agents are plasticizers (especially DEHP, DBP, BBP), heat stabilizers, or antimicrobials incorporated into the polymer. A PVC factory study confirmed this: of 11 workers with allergic contact dermatitis attributed to PVC, 6 were specifically sensitized to phthalate additives. Patch testing is required to identify which specific additive is responsible.
Flexible (plasticized) PVC can cause contact allergy in sensitized individuals due to phthalate plasticizer leaching from the material. The primary concern with phthalates is endocrine disruption — anti-androgenic effects and reproductive toxicity at higher exposures — rather than acute skin toxicity. At consumer product exposure levels, contact allergy is rare. Rigid PVC (no plasticizers) does not cause contact allergy and is not toxic to skin. The EU has imposed strict limits on phthalates in consumer articles under REACH, though US federal regulation remains more limited.
Flexible, soft PVC products contain the highest phthalate concentrations. Common high-phthalate categories include shower curtains, inflatable toys and pool floats, soft children's toys (pre-restriction), vinyl flooring, some shoe insoles and synthetic leather uppers, medical tubing and IV bags (primarily DEHP), and some fashion accessories. Rigid PVC products — pipes, cable insulation, window frames, credit cards — contain little or no plasticizer and are not a concern for phthalate sensitization or endocrine disruption at typical exposure levels. Checking for REACH compliance on product packaging identifies EU-regulated articles that meet phthalate limits.
The EU is prohibiting DEHP in medical devices by July 2030 under the EU Medical Devices Regulation, reflecting concerns about endocrine disruption from DEHP leaching into IV fluids, blood products, and other fluids administered to patients — particularly vulnerable populations including neonates and critically ill patients. DEHP is classified as a Substance of Very High Concern (SVHC) under EU REACH. This regulatory action will drive substitution to DEHP-free plasticizers (DINP, TOTM, and others) in medical-grade PVC products. US hospitals are preparing alternative product sourcing strategies ahead of the EU 2030 DEHP deadline.
Both, but through different mechanisms. As contact allergens, phthalates can sensitize T lymphocytes through the Type IV delayed hypersensitivity mechanism, causing contact dermatitis with repeated skin exposure — though sensitization rates are low. As endocrine disruptors, phthalates (particularly DEHP, DBP, BBP) exhibit anti-androgenic effects and interfere with reproductive hormone signaling at higher systemic exposures. These are separate concerns: contact allergy is a local skin phenomenon, while endocrine disruption is a systemic toxicological effect requiring different risk assessment frameworks. Patch testing can confirm the contact allergy dimension while endocrine risk is addressed separately by your physician.
The key diagnostic step is patch testing with a board-certified dermatologist. Because PVC polymer cannot cause contact allergy, a positive reaction to a PVC product must be attributed to its additives — and patch testing can identify which specific phthalate or additive is responsible. Standard baseline series do not include phthalates; extended testing is required when PVC-associated contact dermatitis is clinically suspected. Without patch testing, switching away from PVC products may eliminate symptoms but leaves the specific allergen unconfirmed and future product decisions poorly guided.
The EU and US CPSIA have permanently banned DEHP, DBP, and BBP in children's toys at concentrations above 0.1% specifically because of endocrine disruption concern — not primarily allergy. True contact sensitization from toy mouthing or skin contact is rare in children. The concern is systemic phthalate exposure through mouthing and ingestion rather than contact allergy. Compliant toys from major manufacturers do not contain restricted phthalates; toys from non-compliant sources (some imports) may still contain restricted phthalates and should be assessed carefully.
For flexible skin-contact applications: silicone rubber (watchstraps, wristbands, medical tubing, sealants), thermoplastic elastomers (TPE/TPR) for footwear and handles, polyurethane for flooring and some upholstery, and natural materials (leather, cotton, wood) where applicable. For flooring: linoleum (natural linseed oil-based), cork, hardwood, or low-VOC carpet are alternatives to vinyl/PVC flooring. For medical devices: polyurethane, polyethylene, and silicone tubing are DEHP-free options increasingly available as the EU 2030 DEHP deadline approaches. A product switch guided by patch test results ensures the alternative material is both phthalate-free and free of other contact allergens you may be sensitized to.
No — not all plastics contain phthalates or the same additives. Polypropylene (PP), high-density polyethylene (HDPE), and silicone do not contain phthalate plasticizers and are generally safe for phthalate-sensitized individuals. The avoidance is targeted: flexible, softened PVC products (which require plasticizers to achieve flexibility) represent the primary risk, not all plastics broadly. Patch testing to identify your specific allergen is the most accurate guide to which products to avoid going forward. Your dermatologist can confirm which plastics are safe after identifying your specific phthalate allergen through extended patch testing.
Medical References
- [1]Andersen KE, et al. Allergic contact dermatitis in PVC factory workers. Contact Dermatitis. 1985;12(5):276–280.
- [2]European Chemicals Agency (ECHA). Restriction of DEHP, DBP, BBP, and DIBP under REACH Annex XVII. ECHA, 2020.
- [3]Frederiksen H, et al. Phthalate exposure and urinary concentrations of phthalate metabolites in humans. Int J Androl. 2012;35(3):398–406.
- [4]European Commission. Medical Devices Regulation (EU) 2017/745 — DEHP restrictions effective 2030. Official Journal of the European Union, 2017.
- [5]Bornehag CG, et al. The association between asthma and allergic symptoms in children and phthalates in house dust: a nested case-control study. Environ Health Perspect. 2004;112(14):1393–1397.
- [6]Warshaw EM, et al. North American Contact Dermatitis Group patch test results: 2017–2018. Dermatitis. 2021;32(2):111–123.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Ready to treat your PVC allergies for good?
Get a personalized treatment plan from board-certified allergists, delivered to your door.
Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.